At Beacon Therapeutics, we are committed to developing products that bring new, innovative gene therapies, like AGTC-501 (laruparetigene zovaparvovec), to patients with serious diseases with no or limited treatment options.
Currently, Beacon Therapeutics does not offer an expanded access program and is not accepting expanded access requests for our investigational products, including AGTC-501.
We understand patient interest in accessing AGTC-501 outside of clinical trials and prior to regulatory approval. However, participation in one of our clinical trials is currently the most appropriate way to access our investigational products. Please see ClinicalTrials.gov and the Beacon Clinical Trials webpage for publicly available information related to Beacon Therapeutics’ ongoing clinical trials.
If you have any questions about Beacon Therapeutics’ EA policy, please contact expandedaccess@beacontx.com